In the last trading session, 1.91 million Phathom Pharmaceuticals Inc (NASDAQ:PHAT) shares changed hands as the company’s beta touched 0.01. With the company’s per share price at $4.09 changed hands at $0.61 or 17.39% during last session, the market valuation stood at $285.19M. PHAT’s last price was a discount, traded about -381.91% off its 52-week high of $19.71. The share price had its 52-week low at $2.21, which suggests the last value was 45.97% up since then.
Analysts gave the Phathom Pharmaceuticals Inc (PHAT) stock a consensus recommendation rating of Buy, calculated at a mean rating of 1.25. If we narrow down to specifics, the data shows that 2 out of 10 analysts rate the stock as a Sell, with a further 0 assigning it an Overweight rating. Of the remaining, 2 recommended PHAT as a Hold, 6 felt it is a Buy and 0 rated the stock as Underweight. Phathom Pharmaceuticals Inc’s EPS for the current quarter is expected to be -0.88.
Phathom Pharmaceuticals Inc (NASDAQ:PHAT) trade information
Instantly PHAT was in green as seen at the end of in last trading. With action 30.10%, the performance over the past five days has been green. The company’s shares are showing year-to-date downside of -49.69%, with the 5-day performance at 30.10% in the green. However, in the 30-day time frame, Phathom Pharmaceuticals Inc (NASDAQ:PHAT) is -3.31% down.
The consensus price target for the stock as assigned by Wall Street analysts is 18, meaning bulls need an upside of 77.28% from its current market value. According to analyst projections, PHAT’s forecast low is 18 with 18 as the target high. To hit the forecast high, the stock’s price needs a -340.1% plunge from its current level, while the stock would need to soar -340.1% for it to hit the projected low.
Phathom Pharmaceuticals Inc (PHAT) estimates and forecasts
Year-over-year growth is forecast to reach 188.75% up from the last financial year.
Consensus estimates given by 7 financial analysts project the company’s revenue in the current quarter to hit an average of 35.65M. 7 analysts are of the opinion that Phathom Pharmaceuticals Inc’s revenue for the current quarter will be 42.62M. The company’s revenue for the corresponding quarters a year ago was 7.32M and 16.35M respectively. According to analysts, the company will likely register a growth in its current quarter sales, forecast at 386.71%. The estimates for the next quarter sales put growth at 160.64%.
Looking at the company’s year-on-year earnings, data shows that the past 5-year has an earnings growth rate of 12.50%. The 2025 estimates are for Phathom Pharmaceuticals Inc earnings to increase by 42.60%.
PHAT Dividends
Phathom Pharmaceuticals Inc is expected to release its next quarterly earnings report in June.
MEDICXI VENTURES MANAGEMENT (JERSEY) LTD holds the second largest percentage of outstanding shares, with 12.7473% or 7.46 million shares worth $76.89 million as of 2024-06-30.
Among Mutual Funds, the top two as of Jan 31, 2025 were AIM Intl Mutual Fd.s -Invesco Global Fd. and Prudential Sector Funds, Inc.-PGIM Jennison Health Sciences Fund . With 1.98 shares estimated at $8.07 million under it, the former controlled 2.83% of total outstanding shares. On the other hand, Prudential Sector Funds, Inc.-PGIM Jennison Health Sciences Fund held about 2.55% of the shares, roughly 1.78 shares worth around $7.28 million.
